Penile Implant Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Penile implant surgery (penile prosthesis implantation) is the definitive surgical treatment for erectile dysfunction that has not responded to oral medications, vacuum erection devices, or intracavernosal injections. It consistently achieves the highest patient and partner satisfaction rates of any ED treatment modality — 90–95% at 5 years — and provides reliable, on-demand erections without requiring pharmaceutical premedication.

Two main prosthesis types are used clinically. The inflatable penile prosthesis (IPP) is the most widely implanted: the three-piece IPP consists of paired inflatable cylinders placed inside the corpora cavernosa, a fluid reservoir placed beneath the rectus abdominis muscle in the retropubic space (or submuscularly in revision cases), and a pump mechanism concealed in the scrotum. The patient squeezes and releases the scrotal pump to transfer saline from reservoir to cylinders, creating an erection; deflation is achieved by pressing a release valve. Leading brands are Boston Scientific AMS 700 series (LGX — length-expanding; CX/CXR — girth-expanding; MS — malleable-feeling) and Coloplast Titan (One-Touch Release pump, Titan Touch with hydrophilic coating). The two-piece IPP eliminates the separate reservoir (fluid stored in the rear tip of cylinders) — simpler but less rigidity and deflation than three-piece.

The malleable (semi-rigid) penile prosthesis consists of paired silicone rods with a bendable metal core implanted in the corpora; the penis is manually bent upward for intercourse and downward for concealment. It is always in a firm state, which can complicate concealment, but is ideal for men with limited manual dexterity (quadriplegia, severe arthritis), elderly men, and those requiring a simpler surgical approach. Leading malleable brands include AMS Spectra and Coloplast Genesis. Surgery is performed under spinal or general anesthesia via penoscrotal or infrapubic incision and takes 45–90 minutes.

Penile implant surgery is indicated for men with erectile dysfunction that is refractory to conservative, pharmacological, and minimally invasive therapies. Established indications include failure of or intolerance to PDE5 inhibitors (sildenafil, tadalafil, vardenafil) and intracavernosal injection therapy (alprostadil, tri-mix) — the two primary non-surgical treatment steps.

Post-radical prostatectomy erectile dysfunction unresponsive to penile rehabilitation (PDE5i + vacuum device) is one of the most common indications, particularly following non-nerve-sparing procedures. Peyronie's disease with associated severe erectile dysfunction is a primary indication, as prosthesis insertion combined with manual modeling (or plaque incision and grafting in complex cases) simultaneously corrects penile curvature and restores erection.

Corporal fibrosis from prior prolonged priapism or long-term intracavernosal injection use creates fibrotic corpora that prevent normal erection; dilating fibrotic corporal tissue during prosthesis placement requires specialized surgical experience. Fournier's gangrene sequelae and radiation-induced ED following prostate cancer treatment are additional indications. Spinal cord injury-related ED, diabetic ED refractory to maximal medical therapy, and ED secondary to severe bilateral pudendal arterial disease (confirmed on penile Doppler ultrasonography with peak systolic velocity <25 cm/s) are all appropriate indications. Penile implant may also be offered to transgender men (FTM) as part of phalloplasty to provide rigidity.

Penile implant candidacy requires confirmation of refractory ED after adequate trials of at least two non-surgical treatment modalities, or clear contraindications to those treatments. The AUA Erectile Dysfunction Guideline recommends shared decision-making with thorough counselling on both the permanence of the procedure (natural erection mechanism is destroyed during corporal dilation) and realistic expectations about outcomes.

Mandatory pre-operative workup includes: urinalysis and urine culture (active UTI or bacteriuria is absolute contraindication), complete blood count, coagulation studies (PT/INR, aPTT), comprehensive metabolic panel, HbA1c (diabetic patients — optimal glycemic control strongly desired, HbA1c <8% reduces infection risk), skin assessment for candidal intertrigo or skin infection in the genital or perineal area, and cardiopulmonary fitness assessment for anesthesia. Penile biodimensional assessment (stretched penile length, flaccid and erect girth measurements) guides cylinder model and size selection.

Contraindications: active urinary tract infection or skin infection in the surgical field (absolute — surgery must be postponed); uncorrected bleeding disorder; active genital malignancy; urethral stricture requiring concurrent repair. Relative contraindications: uncontrolled diabetes (HbA1c >10%), immunosuppression (HIV with CD4 <200, active chemotherapy), poor surgical fitness. Informed consent discussion must cover: irreversibility, infection risk and need for device explantation if infection occurs, mechanical failure and revision surgery rates, penile shortening (average 1–2 cm reduction vs pre-ED erected length), and partner involvement in counselling is strongly recommended.

Penile prostheses fall into three main categories, each with distinct mechanical characteristics, advantages, and trade-offs:

• Three-piece inflatable prosthesis (IPP): The gold standard — comprises two inflatable cylinders placed in the corpora cavernosa, a fluid reservoir implanted beneath the rectus muscle, and a scrotal pump. Squeezing the pump transfers saline from reservoir to cylinders, creating a natural-looking erection. Deflation via a release valve returns fluid to the reservoir. Models include the AMS 700 LGX (with penile length expansion), AMS 700 CX (girth expansion, minimal length), and Coloplast Titan (hydrophilic coating). Provides the most natural appearance when flaccid and erect; highest patient satisfaction rates (90–95%).
• Two-piece inflatable prosthesis: Reservoir is incorporated into the pump, eliminating abdominal reservoir placement. Simpler surgery and suitable for patients with prior pelvic surgery or scarring. Slightly less rigidity and flaccidity compared to three-piece; examples include AMS Ambicor. Preferred in high-risk patients or those with prior pelvic surgery where abdominal reservoir placement is challenging.
• Semi-rigid (malleable) prosthesis: Paired silicone rods with a flexible silver wire core that can be bent up for erection and down for concealment. No mechanical components to fail. Lowest cost, simplest implantation and repair. Preferred in elderly patients, those with limited dexterity, or developing-world settings where device replacement is difficult. Permanently semi-rigid cylinder can cause concealment issues.
• Surgical approach: Penoscrotal incision (most common — excellent cylinder access, accommodates reservoir) or infrapubic incision (better reservoir visualization, lower infection risk but limited pump placement). Surgery takes 45–90 minutes under spinal or general anaesthesia. Antibiotic-impregnated (InhibiZone, Titan Touch) coatings have reduced infection rates to approximately 1%.
• Revision and salvage surgery: Infected prostheses requiring explantation are managed with simultaneous reimplantation using Mulcahy's salvage protocol (copious irrigation + immediate new device implantation), which achieves 80–85% success rates in avoiding secondary scarring.

Penile implant surgery offers unmatched patient satisfaction among all ED treatment options. Multiple large-scale studies and registry data confirm 90–95% patient satisfaction and 85–95% partner satisfaction at 5 years post-implantation. The EDITS (Erectile Dysfunction Inventory of Treatment Satisfaction) score for penile prosthesis consistently exceeds those for all oral and injectable ED therapies. Unlike PDE5 inhibitors or injections, the implant provides on-demand erections without planning or pharmaceutical side effects — often described by patients as restoring spontaneity to their sex life.

Mechanical device survival has improved markedly with modern prostheses. The AMS 700 LGX and Coloplast Titan demonstrate 10-year mechanical survival of approximately 72–80%, meaning roughly 80% of men will not need revision surgery within a decade. Antibiotic-coated devices (InhibiZone coating on AMS implants, hydrophilic coating on Coloplast Titan Touch) have reduced clinically significant infection rates from 2–3% to approximately 1% or less in non-diabetic patients.

For men with Peyronie's disease, simultaneous cylinder placement with manual modeling corrects curvature in 70–85% of cases without additional grafting, addressing both the ED and deformity in a single operation. Post-prostatectomy patients with corporal fibrosis benefit significantly from early implantation (within 24 months of prostatectomy) before progressive fibrosis limits cylinder sizing. Psychological benefits are well-documented: improvements in self-esteem, depression scores, relationship satisfaction, and overall quality of life measures are consistently reported in follow-up studies.

Infection is the most feared complication of penile prosthesis surgery, occurring in 1–3% of non-diabetic men and 2–5% of men with diabetes in modern series. Infection typically presents within 1–3 months of surgery with signs including erythema, swelling, induration, and pain — or late presentations of erosion through skin or urethra. When infection occurs, the entire device must be removed; immediate salvage replacement using the Mulcahy Rescue Procedure (copious antibiotic irrigation followed by immediate reimplantation) achieves 84–92% success in select cases and avoids the significant corporal fibrosis that develops during an unimplanted interval.

Mechanical failure requiring surgical revision occurs in approximately 5–15% of patients at 10 years; causes include cylinder aneurysm (focal weakening), tubing kink or rupture, pump malfunction, or reservoir herniation. Autoinflation (spontaneous cylinder inflation) is more common with two-piece designs and may cause embarrassing partial erections. Cylinder or reservoir erosion through the urethra, glans, or skin is rare but serious, typically presenting months to years post-implant.

Penile shortening of 1–2 cm compared to pre-disease erect length is nearly universal and results from corporeal fibrosis occurring during the ED period prior to implantation — not from the surgery itself. Patients should understand this represents loss from their previous healthy state, not from the prosthesis. Changes in penile sensation (typically not impaired as prosthesis is placed within the corpora, not affecting dorsal nerve) are uncommon. Glans engorgement during artificial erection is less complete than natural erection. Anesthesia risks, wound complications, scrotal hematoma (<1%), and prolonged pain are general surgical risks. Explantation without replacement for infection results in significant penile shortening and scarring that may complicate future reimplantation.

Post-operative care is structured to allow complete healing before device activation:

• Immediate post-op (Days 1–7): The device is left in the inflated or partially inflated position to minimize dead space and reduce risk of scar tissue around cylinders. Drains (if placed) removed at 24–48 hours. Ice packs reduce scrotal oedema. Pain is managed with oral analgesics — moderate discomfort typically lasting 5–10 days.
• Weeks 2–4: Wound healing and resolution of scrotal swelling. Patients are taught device cycling (inflate/deflate) at 2–4 weeks to prevent adhesion and familiarize with the pump mechanism. Light activities resume.
• 6-week follow-up: Device activation for sexual intercourse approved once wound healing is confirmed and patient is comfortable. Partner education on device operation is strongly recommended at this visit.
• Long-term monitoring: Annual review assesses device functionality, patient satisfaction, and cylinder integrity. Mechanical revision rates are approximately 5–10% at 10 years. Patients should immediately report penile curvature changes, pump migration, or difficulty inflating/deflating as early signs of mechanical issues.
• Psychosocial outcomes: Validated outcome tools (EDITS, IIEF) are used at 3, 12, and 36 months. Psychosexual counselling should accompany physical recovery to optimize intimacy and relationship outcomes.

Penile implant surgery costs include three components: surgical team fees (urologist, anesthesiologist), hospital and operating room costs, and the implant device cost itself. The AMS 700 and Coloplast Titan devices cost $3,000–7,000 wholesale — this device cost is present regardless of geography and represents a floor for total procedure costs.

India: Total procedure cost (surgeon + hospital + device) ranges $6,000–15,000 for inflatable three-piece penile prosthesis at accredited centers such as Fortis, Apollo, Medanta, and Max Hospitals. India offers the lowest cost globally while using authentic AMS or Coloplast devices imported from USA. Turkey: $6,000–12,000, with experienced prosthetic urologists at major Istanbul and Ankara urology centers. Thailand: $8,000–18,000, particularly at Bumrungrad International or Bangkok Hospital. Mexico: $8,000–15,000 at specialist centers in Mexico City and Tijuana catering to medical tourists from the USA.

USA: Total costs range $20,000–40,000 including all fees; insurance coverage varies — Medicare Part B covers penile prosthesis for erectile dysfunction caused by organic disease, diabetes, or post-prostatectomy ED when medical necessity is documented. Many private insurers cover it similarly. UK: NHS does not routinely fund penile prosthesis for most indications; private surgical costs in the UK are £15,000–30,000. Malleable prosthesis surgery costs approximately 20–30% less than inflatable across all geographies due to shorter operative time and lower device cost.

Before proceeding to prosthesis surgery, all non-surgical and minimally invasive ED options should be exhausted:

• PDE5 inhibitors (oral medications): Sildenafil, tadalafil, vardenafil, and avanafil are first-line therapy. A penile prosthesis is generally not recommended unless at least two PDE5 inhibitors at adequate doses have failed or are contraindicated.
• Intracavernosal injections (ICI): Tri-mix or alprostadil self-injection achieves erections in >85% of men regardless of etiology and is often the last non-surgical step before implantation. Many men maintain long-term injection programs without needing surgery.
• Vacuum erection devices (VED): A low-cost, non-invasive option producing mechanically reliable erections through negative pressure. Particularly suitable for older men, those on anticoagulants, or men seeking to avoid surgery.
• Low-intensity shockwave therapy (Li-ESWT): May restore spontaneous erectile function in mild-to-moderate vasculogenic ED through neo-angiogenesis, potentially reducing dependence on medications or devices.
• Psychosexual therapy: Strongly recommended for men with significant psychological contributions to ED, either alone or alongside other treatments. Cognitive-behavioral sex therapy addresses performance anxiety, intimacy avoidance, and relationship dynamics.